PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Overview of peptides • Peptide synthesis • Optimization of peptides • Stabilization of peptides • PART 06: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 07: Market segmentation based on route of administration • Parenteral • Oral • Pulmonary • Mucosal PART 08: Market segmentation by drug class • Somatostatins • Vasopressin • Calcitonins • Luteinizing hormone (LH)-releasing hormone (LHRH) • Glucagon and analogs • Insulins • Other PART 09: Market segmentation by synthesis technology • Liquid-phase peptide synthesis • Solid-phase peptide synthesis • Hybrid peptide synthesis PART 10: Geographical segmentation • Global peptide therapeutics market segmentation by geography 2015-2020 • Peptide therapeutics market in Americas • Peptide therapeutics market in EMEA • Peptide therapeutics market in APAC PART 11: Market drivers • Increase in patient population • Advances in peptide synthesis technology • Promising pipeline • Unmet medical needs • Increase in healthcare spending PART 12: Impact of drivers PART 13: Market challenges • High cost of therapy • Adverse side effects • Stringent regulatory compliances • Intense market competition PART 14: Impact of drivers and challenges PART 15: Market trends • Growing popularity • Shifting focus toward untapped markets • Contract manufacturing • Increase in public awareness PART 16: Vendor landscape • Competitive scenario • Eli Lilly • Novo Nordisk • Sanofi • Takeda Pharmaceutical • Teva Pharmaceuticals • Other prominent vendors PART 17: Appendix • List of abbreviations PART 18: Explore Technavio List of Exhibits Exhibit 01: Product offerings Exhibit 02: SWOT analysis: Peptide therapeutics Exhibit 03: Steps involved in peptide synthesis Exhibit 04: Optimization of peptide synthesis Exhibit 05: Methods used to stabilize peptides Exhibit 06: Global peptide therapeutics market 2015-2020 ($ billions) Exhibit 07: Five forces analysis Exhibit 08: Global peptide therapeutics market segmentation based on route of administration Exhibit 09: Global peptide therapeutics market segmentation by route of administration 2015 Exhibit 10: Global peptide therapeutics market segmentation by drug class Exhibit 11: Global peptide therapeutics market segmentation by synthesis technology Exhibit 12: Global peptide therapeutics market segmentation by geography 2015 Exhibit 13: Peptide therapeutics market revenue by geography 2015-2020 ($ billions) Exhibit 14: Peptide therapeutics market in Americas 2015-2020 ($ billions) Exhibit 15: Peptide therapeutics market in EMEA 2015-2020 ($ billions) Exhibit 16: Peptide therapeutics market in APAC 2015-2020 ($ billions) Exhibit 17: Global peptide therapeutics market: YoY growth and revenue based on geography 2015-2020 Exhibit 18: Impact of drivers Exhibit 19: Impact of drivers and challenges Exhibit 20: El Lilly: YoY growth rate and revenue of Humalog 2012-2014 ($ billions) Exhibit 21: Eli Lilly: YoY growth rate and revenue of Cialis 2012-2014 ($ billions) Exhibit 22: Eli Lilly: YoY growth rate and revenue of Cymbalta 2012-2014 ($ billions) Exhibit 23: Eli Lilly: YoY growth rate and revenue of Humulin 2012-2014 ($ billions) Exhibit 24: Eli Lilly: YoY growth rate and revenue of Forteo 2012-2014 ($ billions) Exhibit 25: Eli Lilly: Key takeaways Exhibit 26: Novo Nordisk: YoY growth rate and revenue of NovoLog/NovoRapid 2012-2014 ($ billions) Exhibit 27: Novo Nordisk: Geographical split of revenues of NovoLog 2014 Exhibit 28: Novo Nordisk: YoY growth rate and revenue of NovoMix/NovoLog mix 2012-2014 ($ billions) Exhibit 29: Novo Nordisk: Geographical split of revenues of NovoMix 2014 Exhibit 30: Novo Nordisk: YoY growth rate and revenue of Norditropin 2012-2014 ($ billions) Exhibit 31: Novo Nordisk: Geographical split of revenues of Norditropin 2014 Exhibit 32: Novo Nordisk: YoY growth rate and revenue of Prandin 2012-2014 ($ millions) Exhibit 33: Novo Nordisk: Geographical split of revenues of Prandin 2014 Exhibit 34: Novo Nordisk: Key takeaways Exhibit 35: Sanofi: YoY growth rates and revenues of Lantus 2012-2014 ($ billions) Exhibit 36: Sanofi: YoY growth rate and revenue of Amaryl 2012-2014 ($ millions) Exhibit 37: Sanofi: YoY growth rate and revenue of Apidra 2012-2014 ($ millions) Exhibit 38: Sanofi: YoY growth rate and of Insuman 2012-2014 ($ millions) Exhibit 39: Sanofi: YoY revenue of Lyxumia 2013-2014 ($ millions) Exhibit 40: Sanofi: Key takeaways Exhibit 41: Takeda Pharmaceutical: YoY revenue of Velcade 2013-2014 ($ billions) Exhibit 42: Takeda Pharmaceutical: YoY revenue of Leuprorelin 2013-2014 ($ billions) Exhibit 43: Takeda Pharmaceutical: YoY revenue of Nesina 2013-2014 ($ millions) Exhibit 44: Takeda Pharmaceutical: YoY revenue of TachoSil 2013-2014 ($ millions) Exhibit 45: Takeda Pharmaceutical: Key takeaways Exhibit 46: Teva Pharmaceuticals: YoY growth rate and revenue of Copaxone 2012-2014 ($ billions) Exhibit 47: Teva Pharmaceuticals: Key takeaways

Eli Lilly, Novo Nordisk, Sanofi, Takeda Pharmaceutical, Teva Pharmaceuticals, AbbVie, Advanced Accelerator Applications, Akashi Therapeutics, Amgen, Anthera Pharmaceuticals, AstraZeneca, Bachem, Bristol-Myers Squibb, Cardiorentis, Corden Pharma International, Debiopharm, Derma Sciences, GlaxoSmithKline, Hanmi Pharmaceutical, Insmed, Ipsen, Johnson & Johnson, Lonza, Mallinckrodt, MolMed, Merck, Novartis, Nymox Pharmaceutical, Par Pharmaceuticals, PeptiDream, Polypeptide Group, Radius Health, Repligen, Roche, SciClone, Shire, The Medicines Company, Transition Therapeutics, X-Gen Pharmaceuticals, Zealand Pharma, Zydus Cadila.